Edition:
United States

Versartis Inc (VSAR.OQ)

VSAR.OQ on NASDAQ Stock Exchange Global Select Market

2.45USD
15 Jun 2018
Change (% chg)

-- (--)
Prev Close
$2.45
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
65,727
52-wk High
$22.10
52-wk Low
$1.35

Chart for

About

Versartis, Inc. is an endocrine-focused biopharmaceutical company. The Company is engaged in developing a long-acting form of recombinant human growth hormone, somavaratan (VRS-317), for growth hormone deficiency (GHD), an orphan disease. The Company's first indication for somavaratan is pediatric GHD. The Company may develop... (more)

Overall

Beta: 2.42
Market Cap(Mil.): $88.40
Shares Outstanding(Mil.): 36.08
Dividend: --
Yield (%): --

Financials

  VSAR.OQ Industry Sector
P/E (TTM): -- 240.92 34.18
EPS (TTM): -2.73 -- --
ROI: -89.11 -5.87 13.17
ROE: -95.74 -7.71 15.15

BRIEF-Versartis Q1 Loss Per Share $0.25

* CASH, CASH EQUIVALENTS, AND SHORT-TERM INVESTMENTS WERE $74.7 MILLION AS OF MARCH 31, 2018 Source text for Eikon: Further company coverage:

May 08 2018

BRIEF-Versartis Says Board Approved Plan Of Termination To Eliminate A Number Of Positions Effective Oct 20, 2017

* VERSARTIS SAYS IN OCTOBER 2017, BOARD APPROVED PLAN OF TERMINATION TO ELIMINATE A NUMBER OF POSITIONS EFFECTIVE OCT 20, 2017 - SEC FILING

May 08 2018

BRIEF-Versartis Q4 Earnings Per Share $0.87

* VERSARTIS REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

Mar 01 2018

BRIEF-Advent Life Sciences Reports 4.5 Pct Passive Stake In Versartis Inc

* ADVENT LIFE SCIENCES LLP REPORTS A 4.5 PERCENT PASSIVE STAKE IN VERSARTIS, INC. AS OF DEC 31, 2017 - SEC FILING Source text - http://bit.ly/2EuDXO8 Further company coverage:

Feb 08 2018

Earnings vs. Estimates